Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) FCF Margin (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of FCF Margin data on record, last reported at 292947.03% in Q3 2025.

  • For Q3 2025, FCF Margin fell 29243185.0% year-over-year to 292947.03%; the TTM value through Sep 2025 reached 5600.74%, up 573502.0%, while the annual FY2024 figure was 411.63%, 30475.0% down from the prior year.
  • FCF Margin reached 292947.03% in Q3 2025 per CAPR's latest filing, down from 58706.66% in the prior quarter.
  • Across five years, FCF Margin topped out at 1340.85% in Q4 2024 and bottomed at 292947.03% in Q3 2025.
  • Average FCF Margin over 5 years is 24456.41%, with a median of 390.2% recorded in 2022.
  • Peak YoY movement for FCF Margin: soared 328386bps in 2023, then plummeted -29243185bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 2370.08% in 2021, then surged by 67bps to 791.34% in 2022, then skyrocketed by 87bps to 100.53% in 2023, then skyrocketed by 1434bps to 1340.85% in 2024, then crashed by -21948bps to 292947.03% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 292947.03% in Q3 2025, 58706.66% in Q1 2025, and 1340.85% in Q4 2024.